Millennium Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Millennium Management’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-77,006	Closed	-$127K	–	7896
2022 Q1	$127K	Sell	77,006 -48,702	-39%	-$86.9K	﹤0.01%	6041
2021 Q4	$300K	Buy	+125,708	New	+$512K	﹤0.01%	5546
2021 Q2	–	Sell	-13,665	Closed	-$111K	–	7375
2021 Q1	$111K	Sell	13,665 -29,699	-68%	-$324K	﹤0.01%	5672
2020 Q4	$395K	Buy	+43,364	New	+$356K	﹤0.01%	4381
2020 Q2	–	Sell	-12,658	Closed	-$78K	–	4790
2020 Q1	$78K	Buy	+12,658	New	+$82.6K	﹤0.01%	3602
2019 Q4	–	Sell	-21,406	Closed	-$161K	–	4786
2019 Q3	$161K	Sell	21,406 -7,283	-25%	-$63.2K	﹤0.01%	3853
2019 Q2	$333K	Sell	28,689 -59,420	-67%	-$865K	﹤0.01%	3484
2019 Q1	$1.28M	Buy	+88,109	New	+$1.21M	﹤0.01%	2711

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Millennium Management's KLDO Position: Q2 2022 in Review

Millennium Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 77,006 shares — an estimated $127K sold.

Millennium Management first reported a position in KLDO in Q1 2019 and held it in 8 quarters. The position peaked at $1.28M in Q1 2019. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

Millennium Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Millennium Management sold 77,006 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $127K.
Millennium Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 8 quarters.
Millennium Management's Kaleido Biosciences, Inc. Common Stock position peaked at $1.28M in Q1 2019.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Millennium Management's 13F filing for Q2 2022, filed 15 Aug 2022.